Prodrome Sciences Inc.

Detect

Prodrome Sciences Inc. develops blood-based tests and technology to detect disease prodromes. The technology is designed for high-volume, population-based screening and early disease detection programs. Our technology is novel and disruptive and will change the way governments and healthcare providers manage and implement disease screening and treatment programs.

Dr. Dayan Goodenowe’s patented complex sample analysis technology has been used to study blood samples from thousands of healthy and diseased persons from around the world. Using this unique technology, Dr. Goodenowe discovered numerous biochemical changes associated with diseases such as Alzheimer’s and dementia, autism, multiple sclerosis, colorectal cancer, pancreatic cancer, ovarian cancer, and several other diseases. Dr. Goodenowe has patented and published in peer-reviewed scientific journals the biochemical mechanisms by which disease prodromes become disease and how the treatment of disease prodromes can be used to prevent disease. His concept of using prodromes for disease screening has been validated in numerous clinical trial settings. Dr. Goodenowe’s patented technology is now exclusively licensed to Prodrome Sciences.

Dr. Goodenowe founded Prodrome Sciences to create new, commercially-viable, next-generation, prodrome-based diagnostic tests and technologies that can be implemented in laboratories and hospitals around the world.

 

Diagnostics Platform 

Prodrome Sciences’ Diagnostics Platform is a key component to the global distribution and implementation of our diagnostic and therapeutic products. The Platform is a standalone product for installation in laboratories and hospitals world-wide; the system includes sample preparation, mass spectrometry, proprietary software, and direct patient/doctor reporting.

Mass spectrometry is the gold standard to accurately measure molecules in complex biological samples such as human blood. Although Dr. Goodenowe’s technology uses the most advanced mass spectrometry instrumentation, his new process of detecting disease prodromes is simpler and more amenable to commercial implementation than his original patented invention. A sample of your blood is collected and shipped to our laboratory facilities. Then a drop of blood serum is processed by our technicians to extract out the prodrome-identifying molecules. This complex mixture containing thousands of molecules is then injected into a high resolution, high mass accuracy mass spectrometer to determine how much of each prodrome-identifying molecule is in your blood.

The presence of a disease prodrome in your body alters the levels of some of these molecules and causes them to be either higher or lower than normal. Each disease prodrome has a unique set of molecules that change. Our diagnostic software processes the data for each of these sets of molecules to determine whether a specific disease prodrome is present or not and generates a report that indicates if you have a low or high risk of developing the disease.

 

Cancer Prodromes 

Prodrome-CRC

 

Colorectal Cancer Test

The colorectal cancer prodrome is easily detected in only a single drop of blood using Prodrome Sciences’ diagnostic technology. Having the colorectal cancer prodrome means you are high risk for developing colorectal cancer. If the Prodrome-CRC test reveals you do not have the colorectal cancer prodrome, you have a low risk of developing the disease. Persons who test positive for the colorectal cancer prodrome should seek additional testing, such as a colonoscopy, to determine if they have colorectal cancer. Since the presence of the prodrome occurs before the disease, prodrome diagnostic tests ensure that high-risk persons can be monitored so that if the person does get colorectal cancer, it will be detected at the earliest possible stage.

 

Colorectal Cancer

Approximately 141,000 new cases of colorectal cancer are detected and about 49,000 persons die of colorectal cancer each year in the USA making colorectal cancer the second leading cause of cancer related death. Age is the largest risk factor for getting colorectal cancer. Your risk of getting colorectal cancer begins to increase at around age 50 and then continues to increase as you get older.

There are approximately 81 million people in the United States over the age of 50; however, less than 30 percent of these persons comply with the recommended screening tests (colonoscopy or fecal testing), primarily due to the unpleasantness of the available testing procedures. As a result, most colorectal cancer cases are detected at a later stage when the cancer is advanced enough to make you feel sick. Approximately 35,000 of the 49,000 persons who will die of colorectal cancer this year would be alive next year if only their cancer was detected earlier. A simple, accessible blood test is a critical first step to reduce colorectal cancer deaths; current population-based colorectal cancer screening protocols are simply not working.

 

Colorectal Cancer Prodrome

Using Dr. Goodenowe’s patented metabolomics technology, Dr. Goodenowe discovered that there were specific biochemical changes in blood from colorectal cancer patients versus healthy persons (BMC Med. 2010 Jan 19;8:13.). To determine if these changes were being caused by the tumor, Dr. Goodenowe performed two independent clinical trials in colorectal cancer patients before and after surgical removal of their tumor. The biochemical changes remained the same indicating that these changes did not represent the tumor but represented a change in the body that could have caused the cancer (BMC Gastroenterol. 2010 Nov 29;10:140.). Dr. Goodenowe’s subsequent laboratory research showed that these changes reduced anti-cancer and anti-inflammatory activities (J Exp Clin Cancer Res. 2011 May 17;30:59). Dr. Goodenowe then performed a large clinical trial involving over 5000 persons to determine if these biochemical changes (the colorectal cancer prodrome) in a person’s blood sample could be used to identify persons with a high-risk of having and getting colorectal cancer. The results of this study revealed that approximately nine out of ten persons that were diagnosed with colorectal cancer had the colorectal cancer prodrome prior to their diagnosis, demonstrating the potential of prodrome-based tests to identify disease at very early stages. (Int J Cancer. 2013 Jan 15;132(2):355-62).

Prodrome-PAC

 

Pancreatic Cancer Test

The pancreatic cancer prodrome is easily detected in only a single drop of blood using Prodrome Sciences’ diagnostic technology. Having the pancreatic cancer prodrome means you are high risk for developing pancreatic cancer. If the Prodrome-PAC test reveals you do not have the pancreatic cancer prodrome, you have a low risk of developing the disease. Persons over the age of 50 with the pancreatic cancer prodrome have a higher risk of pancreatic cancer than the average person’s risk for colorectal cancer. This means that it is viable and appropriate for persons with the pancreatic cancer prodrome to undergo additional testing to determine if pancreatic cancer is present, which is consistent with the current colorectal cancer screening guidelines. The pancreatic cancer prodrome test makes population-based screening for pancreatic cancer viable for the first time.

 

Pancreatic Cancer

Approximately 44,000 new cases of pancreatic cancer are detected and about 38,000 persons die of pancreatic cancer each year in the USA making pancreatic cancer the fourth leading cause of cancer related death. Like colorectal cancer, age is the largest risk factor for getting pancreatic cancer. However, your risk of getting pancreatic cancer is much lower than your risk of getting colorectal cancer.

The relatively low risk of getting pancreatic cancer is the reason why not everyone is screened for the disease using expensive or invasive imaging technologies, like how we use colonoscopy to screen for colorectal cancer. There is currently no viable population-based screening protocol for pancreatic cancer. Therefore, most people are diagnosed with pancreatic cancer at a late stage when the cancer is advanced enough to make you feel sick and go see your doctor. When the cancer is in an advanced stage it is more difficult to treat. Almost nine out of ten persons diagnosed with pancreatic cancer die of pancreatic cancer.

 

Pancreatic Cancer Prodrome

Using Dr. Goodenowe’s patented metabolomics technology, numerous biochemical changes were observed in the blood of patients diagnosed with pancreatic cancer. These biochemical changes were present in virtually all persons diagnosed with pancreatic cancer (98% accuracy) (BMC Cancer. 2013 Sep 12;13:416) and the best markers for the pancreatic cancer prodrome were evaluated (World J Gastroenterol. 2015 Jun 7;21(21):6604-12).

Prodrome-OVC

 

Ovarian Cancer Test

The ovarian cancer prodrome is easily detected in only a single drop of blood using Prodrome Sciences’ diagnostic technology. Having the ovarian cancer prodrome means you are high risk for developing ovarian cancer. If the Prodrome-OVC test reveals you do not have the ovarian cancer prodrome, you have a low risk of developing the disease. Women in their 40s with the ovarian cancer prodrome are at higher risk of ovarian cancer than the average 50-year-old’s risk of colorectal cancer. These results indicate that screening for the ovarian cancer prodrome should start at age 40. The ovarian cancer prodrome test makes population-based screening for ovarian cancer viable for the first time.

 

Ovarian Cancer

Approximately 21,000 new cases of ovarian cancer are detected and about 14,000 women die of ovarian cancer each year in the USA. Age is the largest risk factor for getting ovarian cancer. However, like pancreatic cancer, the risk of getting ovarian cancer is much lower than the risk of getting colorectal cancer.

The relatively low risk of getting ovarian cancer is the reason why not every woman is screened for the disease using expensive or invasive imaging technologies. There is currently no viable or accepted screening protocol for ovarian cancer in the general population. Therefore, like pancreatic cancer, most women are diagnosed with ovarian cancer at a late stage when it is difficult to treat. Most women diagnosed with ovarian cancer die of ovarian cancer.

Prodrome Sciences researches the ovarian cancer prodrome to understand all the biochemical changes that occur before a person develops the disease.

 

Neurodegeneration Prodrome 

Prodrome-Neuro

Neurodegeneration Prodrome Test

The neurodegeneration prodrome is easily detected in only a single drop of blood using Prodrome Sciences’ diagnostic technology. Having the neurodegeneration prodrome means you are high risk for developing a neurodegenerative disease. If the Prodrome-Neuro test reveals you do not have the neurodegeneration prodrome, you have a low risk of developing a neurodegenerative disease. The risk of developing a neurodegenerative disease, such as Alzheimer’s or Parkinson’s disease, begins to rapidly increase after age 70. Prodrome Sciences recommends testing for the neurodegeneration prodrome to begin at age 60 such that preventative measures can be implemented prior to a significant loss of neuronal reserve.

About Prodrome Sciences Inc.

Prodrome Sciences researches prodromes of diseases – how to detect them, what causes them, and how to return high-risk prodrome states back to a healthy state before the disease develops. We use our advanced diagnostic technology for blood tests to detect disease prodromes and in our natural therapeutic programs to restore an unhealthy, high-risk prodrome state to a healthy, low-risk state. Our goal is to reduce the number of people that develop and die from disease and to promote optimal health.

Keep in touch

©2018 Prodrome Sciences Inc.

Search